Skye Bioscience (SKYE) KOL Event summary

Introduction and agenda

• Event focused on interpreting CBeyond Phase 2a topline, translating clinical readouts, and discussing new preclinical data, with a structured agenda including science updates, KOL panel, and Q&A.

• The session included presentations on science, study design, and expectations for 26-week and 52-week outcomes, followed by expert panel discussion and audience Q&A.

KOL background and credentials

• Panel included Dr. Sean Wharton (anti-obesity clinical experience), Dr. Kenneth Cusi (endocrinologist, obesity expert, CBeyond PI), and Dr. Marcus Goncalves (endocrinologist, biomedical researcher at NYU Langone).

Market insights and analysis

• Surveys of ~60 endocrinologists and PCPs revealed unmet needs in tolerability and chronic use for obesity therapies, highlighting opportunities for monotherapy, combination, and maintenance regimens.

• Better tolerability is seen as key to long-term adherence and market differentiation, especially for patients intolerant to GLP-1 or needing additional weight loss.